European Companies Search Engine
EU funding (€11M): NGS diagnostics in 21st century oncology: the best, for all, at all times Hor1 Jan 2020 EU Research and Innovation programme "Horizon"
Text
NGS diagnostics in 21st century oncology: the best, for all, at all times
oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.
Funded Companies:
Source: https://cordis.europa.eu/project/id/874467
The filing refers to a past date, and does not necessarily reflect the current state.